globe
usa
magnifying-glass
checkbox
g-plus
rss
youtube
fb-round
connect-with-us-in
connect-with-us-twitter
youtube2
facebook
linkedin
twitter
☰
MEDINOL
About Us
NIR Legacy
News
PRODUCTS
EluNIR
NC Gallant
Gallant
ChampioNIR
TECHNOLOGIES
Flexx²
WiZeCell
eDES Coating
Quality Surface
CLINICAL
Clinical Program
WHERE TO BUY
DISTRIBUTORS ZONE
Sign In
CONTACT
CONTACT US
Join Us
The website you have requested may contain information on products or uses of such products that are not approved in your country. For specific product and country information please contact Medinol
Continue
Products
NIRxcell
Clinical
Clinical Program
The PREHAMI Registry
At a Glance
Clinical
Clinical Program
Case Studies
Product Information
Deliverability
Stent Design
QualitySurface
Ordering Information
The PREHAMI Registry
A prospective single-center registry evaluating the outcomes of patients with high-risk acute MI who underwent PCI with the NIRxcell stent
129 patients enrolled in Rome, Italy
Patients undergoing acute MI (STEMI and non-STEMI)
Primary endpoint: MACE in-hospital and at 12 months
Result: The in-hospital MACE was 5.4%, at 6 months it was 13.3% and 17.3% at 12 months. The 12 months rate of TVR was 4.6%
NIRxcell Performance in High Risk AMI Pateints